BioNexus Gene Lab CorpBGLCEarnings & Financial Report
BioNexus Gene Lab Corp is a biotechnology company specializing in molecular diagnostic testing, genetic analysis, and related life science solutions. It caters to healthcare institutions, research organizations, and individual customers, with its primary operational and market focus on the Southeast Asian region.
BGLC Q4 FY2025 Key Financial Metrics
Revenue
$483.8K
Gross Profit
$-4.0K
Operating Profit
$-1.0M
Net Profit
$-1.0M
Gross Margin
-0.8%
Operating Margin
-213.5%
Net Margin
-214.2%
YoY Growth
-80.8%
BioNexus Gene Lab Corp Q4 FY2025 Financial Summary
BioNexus Gene Lab Corp reported revenue of $483.8K (down 80.8% YoY) for Q4 FY2025, with a net profit of $-1.0M (down 197.5% YoY) (-214.2% margin). Cost of goods sold was $487.7K, operating expenses totaled $1.0M.
Key Financial Metrics
| Total Revenue | $483.8K |
|---|---|
| Net Profit | $-1.0M |
| Gross Margin | -0.8% |
| Operating Margin | -213.5% |
| Report Period | Q4 FY2025 |
BioNexus Gene Lab Corp Annual Revenue by Year
BioNexus Gene Lab Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $7.4M).
BioNexus Gene Lab Corp Quarterly Revenue & Net Profit History
BioNexus Gene Lab Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $483.8K | -80.8% | $-1.0M | -214.2% |
| Q3 FY2025 | $2.5M | -3.3% | $-709.0K | -27.9% |
| Q2 FY2025 | $2.3M | +14.5% | $-616.2K | -27.3% |
| Q1 FY2025 | $2.1M | -10.3% | $-623.3K | -29.2% |
| Q4 FY2024 | $2.5M | +11.0% | $-348.3K | -13.8% |
| Q3 FY2024 | $2.6M | +3.0% | $-1.3M | -51.1% |
| Q2 FY2024 | $2.0M | -23.1% | $199.1K | 10.1% |
| Q1 FY2024 | $2.4M | +0.2% | $-103.8K | -4.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.0M | $2.6M | $2.5M | $2.1M | $2.3M | $2.5M | $483760 |
| YoY Growth | 0.2% | -23.1% | 3.0% | 11.0% | -10.3% | 14.5% | -3.3% | -80.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $11.2M | $11.1M | $11.0M | $10.4M | $9.5M | $9.4M | $7.6M | $9.3M |
| Liabilities | $1.8M | $1.6M | $1.6M | $2.1M | $1.7M | $1.9M | $804966 | $637856 |
| Equity | $9.3M | $9.5M | $9.4M | $8.3M | $7.8M | $7.5M | $6.8M | $8.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-37153 | $-672275 | $-1.6M | $219203 | $-824072 | $-737907 | $-1.2M | $961062 |